الفهرس 
Chapter 1: Myeloproliferative neoplasmsOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
Myeloproliferative neoplasms (MPNs) are a group of clonal stem cell
malignancies among the myeloid disorders that are characterized by the
abnormal increase in the production of mature and immature blood cells of one
or more myeloid lineages and that may evolve into acute myeloid leukemia.
For several years, the World Health Organization (WHO) classification
of myeloid neoplasms classified MPNs based on the clinical and laboratory
features. The last revised WHO in 2016 did not significantly change MPNs
since the previous revision but it added a new criteria related to the discoveries
of the new mutations and the improvement in the morphologic features and thus
increased the reliability of diagnoses.
JAK2 V617F mutation in which a valine substituted to phnylalanine at
codon 617 is the most commonly mutation that associated with almost all cases
of PV and about 50%-60% of ET and PMF cases. JAK2 exon 12 reported to be
detected in about 2% of negative-JAK2 V617F in only PV cases. Whereas, the
MPL mutations associated with about 3-5% of nagetive-JAK2V617F ET or
PMF.